Literature DB >> 18240225

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Stéphanie Christen-Zaech1, Roopa Seshadri, Joyce Sundberg, Amy S Paller, Lauren M Pachman.   

Abstract

OBJECTIVE: To determine the association of changes on nailfold capillaroscopy with clinical findings and genotype in children with juvenile dermatomyositis (DM), in order to identify potential differences in disease course over 36 months.
METHODS: At diagnosis of juvenile DM in 61 children prior to the initiation of treatment, tumor necrosis factor alpha (TNFalpha) -308 allele and DQA1*0501 status was determined, juvenile DM Disease Activity Scores (DAS) were obtained, and nailfold capillaroscopy was performed. The disease course was monitored for 36 months. Variations within and between patients were assessed by regression analysis.
RESULTS: At diagnosis, shorter duration of untreated disease (P = 0.05) and a lower juvenile DM skin DAS (P = 0.035) were associated with a unicyclic disease course. Over 36 months, end-row loop (ERL) regeneration was associated with lower skin DAS (P < 0.001) but not muscle DAS (P = 0.98); ERL regeneration and decreased bushy loops were associated with a shorter duration of untreated disease (P = 0.04 for both). At 36 months, increased ERL regeneration (P = 0.007) and improvement of skin DAS (P < 0.001) and muscle DAS (P = 0.025) were associated with a unicyclic disease course.
CONCLUSION: Early treatment of juvenile DM may lead to a unicyclic disease course. The non-unicyclic disease course usually involves continuing skin manifestations with persistent nailfold capillaroscopy changes. The correlation of nailfold capillaroscopy results with cutaneous but not with musculoskeletal signs of juvenile DM over a 36-month period suggests that the cutaneous and muscle vasculopathies have different pathophysiologic mechanisms. These findings indicate that efforts to identify the optimal treatment of cutaneous features in juvenile DM require greater attention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240225      PMCID: PMC2830145          DOI: 10.1002/art.23299

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

Authors:  Rita K Bode; Marisa S Klein-Gitelman; Michael L Miller; Toula S Lechman; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-02-15

3.  Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study.

Authors:  P Dolezalova; S P Young; P A Bacon; T R Southwood
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

4.  Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Authors:  Zivana Tezak; Eric P Hoffman; Jennica L Lutz; Tamara O Fedczyna; Dietrich Stephan; Eric G Bremer; Irina Krasnoselska-Riz; Ajit Kumar; Lauren M Pachman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

5.  TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

Authors:  L M Pachman; M R Liotta-Davis; D K Hong; T R Kinsella; E P Mendez; J M Kinder; E H Chen
Journal:  Arthritis Rheum       Date:  2000-10

6.  Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis.

Authors:  Jennica Lutz; Kristin G Huwiler; Tamara Fedczyna; Toula S Lechman; Susan Crawford; T Randell Kinsella; Lauren M Pachman
Journal:  Clin Immunol       Date:  2002-06       Impact factor: 3.969

7.  Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis.

Authors:  L M Pachman; D L Litt; A H Rowley; J R Hayford; J Caliendo; S Heller; B S Ticho; M Christensen; B Patterson; S R Ytterberg
Journal:  Arthritis Rheum       Date:  1995-10

8.  Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.

Authors:  Rita E Fisler; Marilyn G Liang; Robert C Fuhlbrigge; Ali Yalcindag; Robert P Sundel
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

9.  Course of treated juvenile dermatomyositis.

Authors:  C H Spencer; V Hanson; B H Singsen; B H Bernstein; H K Kornreich; K K King
Journal:  J Pediatr       Date:  1984-09       Impact factor: 4.406

10.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Aneel Gursahaney; Ka-Leung Ngai; Jennifer A Daru; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02-15
View more
  42 in total

1.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

2.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

3.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Authors:  G Esther A Habers; Adam M Huber; Gulnara Mamyrova; Ira N Targoff; Terrance P O'Hanlon; Sharon Adams; Janardan P Pandey; Chantal Boonacker; Marco van Brussel; Frederick W Miller; Annet van Royen-Kerkhof; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

4.  Inflammatory muscle disease assessment.

Authors:  Tim Y-T Lu; Kristine P Ng; David A Isenberg
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 5.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

6.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

7.  Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.

Authors:  Micah J Eimer; Wendy J Brickman; Roopa Seshadri; Rosalind Ramsey-Goldman; David D McPherson; Beverly Smulevitz; Neil J Stone; Lauren M Pachman
Journal:  J Pediatr       Date:  2011-07-23       Impact factor: 4.406

8.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

9.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.

Authors:  Neil Martin; Petra Krol; Sally Smith; Kevin Murray; Clarissa A Pilkington; Joyce E Davidson; Lucy R Wedderburn
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

10.  Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Authors:  Paige W Wolstencroft; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.